ReviewJournal of hematology & oncology2014
The role of telomeres and telomerase in hematologic malignancies and hematopoietic stem cell transplantation.
Review in Journal of hematology & oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- The Effect of Cancer Treatments on Telomere Length: A Systematic Review of the Literature.Journal of the National Cancer Institute · 2018Pooled it
- Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.Leukemia · 2026Trial
- Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets.Journal of hematology & oncology · 2015Trial
- Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress.British journal of haematology · 2026Review
- Telomere Length Abnormality: Investigating Approaches and Correlations with Cancer, Bone Marrow Failure and Hematological Malignancies.Biomedicines · 2025Review
- Article
- Article
- The interplay between telomeric complex members and BCR::ABL1 oncogenic tyrosine kinase in the maintenance of telomere length in chronic myeloid leukemia.Journal of cancer research and clinical oncology · 2023Article
- Spotlight onGenes · 2023Article
- P19 a Parthenin Analog Induces Cell Lineage Dependent Apoptotic and Immunomodulatory Signaling in Acute Lymphoid Leukemia Cells.International journal of molecular and cellular medicine · 2023Article
- Telomere length and telomere repeat-binding protein in children with sickle cell disease.Pediatric research · 2022Article
- Genetics of donor cell leukemia in acute myelogenous leukemia and myelodysplastic syndrome.Bone marrow transplantation · 2021Review
- Targeting Telomere Biology in Acute Lymphoblastic Leukemia.International journal of molecular sciences · 2021Article
- Crucial roles of different RNA-binding hnRNP proteins in Stem Cells.International journal of biological sciences · 2021Review
- Epicardium-Derived Tbx18Frontiers in cardiovascular medicine · 2021Article
- Long noncoding RNA MEG3 blocks telomerase activity in human liver cancer stem cells epigenetically.Stem cell research & therapy · 2020Article
- Differential Regulation of Telomeric Complex byGenes · 2020Article
- Cellular and Molecular Mechanisms of Environmental Pollutants on Hematopoiesis.International journal of molecular sciences · 2020Review
- Short Dysfunctional Telomere Is Highly Predictive of Dismal Outcome in MDS but Not in AML Patients.International journal of hematology-oncology and stem cell research · 2020Article
- Mechanisms and rejuvenation strategies for aged hematopoietic stem cells.Journal of hematology & oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Telomeres are specific nucleoprotein structures at the ends of eukaryotic chromosomes. Telomeres and telomere-associated proteins maintain genome stability by protecting the ends of chromosomes from fusion and degradation. In normal somatic cells, the length of the telomeres gradually becomes shortened with cell division. In tumor cells, the shortening of telomeres length is accelerated under the increased proliferation pressure. However, it will be maintained at an extremely short length as the result of activation of telomerase. Significantly shortened telomeres, activation of telomerase, and altered expression of telomere-associated proteins are common features of various hematologic malignancies and are related with progression or chemotherapy resistance in these diseases. In patients who have received hematopoietic stem cell transplantation (HSCT), the telomere length and the telomerase activity of the engrafted donor cells have a significant influence on HSCT outcomes. Transplantation-related factors should be taken into consideration because of their impacts on telomere homeostasis. As activation of telomerase is widespread in tumor cells, it has been employed as a target point in the treatment of neoplastic hematologic disorders. In this review, the characteristics and roles of telomeres and telomerase both in hematologic malignancies and in HSCT will be summarized. The current status of telomerase-targeted therapies utilized in the treatment of hematologic malignancies will also be reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.